ConductScience.org, home

Trial · NCT01283139

Participant flow12

How many started, completed or left each group, period by period.

PeriodMilestoneGroupParticipantsUnits counted
Overall StudySTARTEDPlacebo108
Overall StudySTARTEDSifalimumab 200 Milligram (mg)108
Overall StudySTARTEDSifalimumab 600 mg109
Overall StudySTARTEDSifalimumab 1,200 mg107
Overall StudyCOMPLETEDPlacebo91
Overall StudyCOMPLETEDSifalimumab 200 Milligram (mg)90
Overall StudyCOMPLETEDSifalimumab 600 mg91
Overall StudyCOMPLETEDSifalimumab 1,200 mg92
Overall StudyNOT COMPLETEDPlacebo17
Overall StudyNOT COMPLETEDSifalimumab 200 Milligram (mg)18
Overall StudyNOT COMPLETEDSifalimumab 600 mg18
Overall StudyNOT COMPLETEDSifalimumab 1,200 mg15

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT01283139/flow